Certara (NASDAQ:CERT) Price Target Cut to $8.00 by Analysts at KeyCorp

Certara (NASDAQ:CERT) had its target price cut by analysts at KeyCorp from $10.00 to $8.00 in a report released on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. KeyCorp’s target price points to a potential upside of 44.14% from the company’s current price.

Several other research analysts also recently weighed in on CERT. Morgan Stanley lowered their target price on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Leerink Partners reiterated an “outperform” rating and issued a $10.00 target price on shares of Certara in a research note on Thursday, February 26th. Barclays reiterated an “equal weight” rating and issued a $8.00 target price on shares of Certara in a research note on Friday, March 6th. TD Cowen reiterated a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Finally, Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a research note on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $10.44.

Certara Stock Performance

CERT opened at $5.55 on Monday. The firm has a market cap of $850.93 million, a price-to-earnings ratio of -555.00 and a beta of 1.62. Certara has a 52 week low of $5.19 and a 52 week high of $15.38. The business’s 50 day moving average is $6.53 and its two-hundred day moving average is $8.87. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The company’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period last year, the firm earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, research analysts predict that Certara will post 0.28 EPS for the current year.

Institutional Trading of Certara

Several hedge funds have recently modified their holdings of the business. AQR Capital Management LLC purchased a new stake in shares of Certara during the 1st quarter worth $259,000. Goldman Sachs Group Inc. boosted its position in shares of Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after purchasing an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Certara by 29.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after purchasing an additional 21,099 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.